{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:29:37Z","timestamp":1783909777094,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.11.024","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T09:41:24Z","timestamp":1639561284000},"page":"173-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Considering human challenge trials for tuberculosis vaccine development"],"prefix":"10.1016","volume":"40","author":[{"given":"Gavriel","family":"Kleinwaks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2021.11.024_b0005","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4161\/hv.20506","article-title":"Size of clinical trials and Introductory prices of prophylactic vaccine series","volume":"8","author":"Weinberg","year":"2012","journal-title":"Human Vacc Immunotherap"},{"issue":"10","key":"10.1016\/j.vaccine.2021.11.024_b0010","first-page":"638","article-title":"Vaxchora: The First FDA-Approved Cholera Vaccination in the United States","volume":"42","author":"Mosley","year":"2017","journal-title":"P & T: Peer-reviewed J Formulary Manage"},{"issue":"12","key":"10.1016\/j.vaccine.2021.11.024_b0015","first-page":"1386","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Douglas","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2021.11.024_b0020","unstructured":"Lovelace Berkeley. Novavax Plunges 84% after Failed Trial, Analysts Downgrade. CNBC, CNBC, 16 Sept. 2016, www.cnbc.com\/2016\/09\/16\/novavax-plunges-80-after-failed-trial-analysts-downgrade.html."},{"issue":"9","key":"10.1016\/j.vaccine.2021.11.024_b0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2021.11.024_b0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/infdis\/jis012","article-title":"A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Gu\u00e9rin","volume":"205","author":"Minassian","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.024_b0035","unstructured":"Robertson Brian. TB Human Challenge Consortium. www.tbvi.eu\/wp-content\/uploads\/2017\/02\/BR_Robertson-TBVI-2017.pdf PowerPoint Presentation."},{"key":"10.1016\/j.vaccine.2021.11.024_b0040","unstructured":"Rohrig Abie, et al. \u201cExploring the Ethics of Tuberculosis Human Challenge Models.\u201d PhilArchive copy v2: https:\/\/philarchive.org\/archive\/ROHETEv2."},{"key":"10.1016\/j.vaccine.2021.11.024_b0045","doi-asserted-by":"crossref","unstructured":"Kabbara Wissam K, et al. Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature. Case Reports Infect Dis 2016;2016: 3617408. https:\/\/doi.org\/10.1155\/2016\/3617408.","DOI":"10.1155\/2016\/3617408"},{"key":"10.1016\/j.vaccine.2021.11.024_b0050","doi-asserted-by":"crossref","unstructured":"Van Der Meeren Oliver, et al. Phase 2b Controlled Trial of M72\/AS01E Vaccine to Prevent Tuberculosis. New Engl J Med 379(17):1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1803484.","DOI":"10.1056\/NEJMoa1803484"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2022.05.058","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T23:17:49Z","timestamp":1674256669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21014699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21014699"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.024","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.vaccine.2022.05.058","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considering human challenge trials for tuberculosis vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}